High volume hemofiltration in critically III patients: Why,when and how?

Contributions to Nephrology

Volumn 144, Issue , 2004, Pages 362-375

  Tetta, Ciro ^a   Bellomo, Rinaldo ^b   Kelluttf, John ^c   Ricci, Zaccaria ^d   Pohlmeier, Robert ^a   Passlick Deetjen, Jutta ^a   Ronco, Claudio ^d  

^a FRESENIUS MEDICAL CARE   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CRITICAL ILLNESS; HEMOFILTRATION; HUMAN; METHODOLOGY; REVIEW;

CRITICAL ILLNESS; HEMOFILTRATION; HUMANS;

EID: 3342996946     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (53)

1. Mehta RL, Mc Donald B, Gabbai FB, et al: A randomized clinical trial for continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154-1163.
2. Liano F, Junco E, Pascual J, et al: The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl 1998;66:S16-S24.
3. Metnitz PG, Krenn CG, Steltzer H, et al: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051-2058.
4. Cohen J: The immunopathogenesis of sepsis. Nature 2002;420:885-891.
5. Hotchkiss RE, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348: 138-150.
6. Tetta C, De Nitti CM, Wratten ML, et al: Do circulating cytokines really matter in sepsis? Kidney Int Suppl 2003;84:S69-S71.
7. Tetta C, Bellomo R, Ronco C: Artificial organ treatment for multiple organ failure, acute renal failure, and sepsis: Recent new trends. Artif Organs 2003;27:202-213.
8. Taylor FB, Haddad PA, Hack E, et al: Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med 2001;29:326-334.
9. Pinsky MR: Sepsis: A pro- and anti-inflammatory disequilibrium syndrome. Contrib Nephrol. Basel, Karger, 2001, vol 132, pp 354-366.
10. Cavaillon JM, Adib-Conquy M, Cloez-Tayarani I, Fitting C: Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: A review. J Endotoxin Res 2001;7:85-93.
11. Volk HD, Reinke P, Krausch D, et al: Monocyte deactivation: Rationale for a new therapeutic strategy in sepsis. Intens Care Med 1996;(suppl 4):S474-S481.
12. Ronco C, Ricci Z, Bellomo R: Importance of increased Ultrafiltration volume and impact on mortality: Sepsis and cytokine story and the role of continuous veno-venous hemofiltration. Cur Opin Nephrol Hypern 2001;10:755-761.
13. Goldfarb S, Golper TA: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994;5:228-232.
14. Hoffmann JN, Hartl WH, Deppisch R, et al: Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563-1570.
15. Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA: Complement depletion during haemofiltration with polyacrylonitrile membranes. Nephrol Dial Transplant 1996;11: 117-119.
16. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR: Diffusive vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 1998;26:1995-2000.
17. Ronco C, Tetta C, Lupi A, Galloni E, Bettini MC, Sereni L, Mariano F, DeMartino A, Montrucchio G, Camussi G, LaGreca G: Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995;23:99-107.
18. Mariano F, Tetta C, Guida GE, Triolo G, Camussi G: Hemofiltration reduces the priming activity on neutrophil chemiluminescence in septic patients. Kidney Int 2001;60:1598-1605.
19. Sander A, Armbruster W, Sander B, et al: Haemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intens Care Med 1997;23:878-884.
20. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutler JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10:846-853.
21. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA: Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intens Care Med 1999;25: 903-910.
22. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, LaGreca G, Ingaggiato P, Maggiore U, De Nitti C, Wratten ML, Tetta C: A pilot study on coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-1255.
23. Tetta C, Bellomo R, D'Intini V, et al: Do circulating cytokines really matter in sepsis? Kidney Int Suppl 2003;84:S69-S71.
24. Heering P, Morgera S, Schmilz FJ, et al: Cylokine removal and cardiovascular hemodynamics in seplic palienls wilh conlinuous veno-venous hemofillralion. Inlens Care Med 1997;23:288-296.
25. Pathan N, Sandiford C, Harding SE, Levin M: Characterization of a myocardial depressant factor in meningococcal septicemia. Crit Care Med 2002;30:2191-2198.
26. Pathan N, Hemingway CA, Alizadeh AA, et al: Role of interleukin 6 in myocardial dysfunction in meningococcal septic shock. Lancet 2004;363:203-209.
27. Carlson DL, Lightford E, Bryant DD, et al: Burn plasma mediates cardiac myocyte apoptosis via endotoxin. Am J Physiol 2002;282:H1907-H1914.
28. Grootendorst AF, van Bommel EFH, van der Hoven B, van Leengoed LAM, van Osta ALM: High volume hemofiltration improves right ventricular function of endotoxin-induced shock in the pig. Intens Care Med 1992; 18:235-240.
29. Grootendorst AF, van Bommel EFH, van der Hoven B, et al: High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 1992;7:67-75.
30. Grootendorst AF, van Bommel EFH, van Leengoed LAM, et al: High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock 1994;2:72-78.
31. Grootendorst AF, van Bommel EF, van Leengoed LA, et al: Infusion of ultrafiltrate from endo-toxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993;8:161-169.
32. Nagashima M, Shin'oka T, Nollert G, et al: High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermie circulatory arrest. Circulation 1998;98(suppl 19):II378-II384.
33. Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993;21:914-924.
34. Rogiers P, Zhang H, Smail N, et al: Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999;27:1848-1855.
35. Yekebas EF, Eisenberger CF, Ohnesorge H, et al: Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001;29:1423-1430.
36. Nagashima M, Shin'oka T, Nollert G, et al: High volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermie circulatory arrest. Circulation 1998;98(suppl 19):II378-II384.
37. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000; 356:26-30.
38. Chertow GM, Lazarus JM, Paganini EP, et al: Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Failure Study Group. J Am Soc Nephrol 1998;9:692-698.
39. Journois D, Israel Biet D, Pouard P, et al: High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996;85: 965-976.
40. Oudemans-van Straaten HM, Bosman RJ, et al: Outcome of critically ill patients treated with intermittent high-volume hemofiltration: A prospective cohort analysis. Intens Care Med 1999;25: 814-821.
41. Cole L, Bellomo R, Journois D, et al: High-volume hemofiltration in human septic shock. Intens Care Med 2001;27:978-986.
42. Honore PM, Jamez J, Wauthier M, et al: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-3587.
43. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J: Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med 2002;30:2205-2211.
44. Jamal JA, Hoh J, Bastani B: Removal of morphine with the high-efficiency and high-flux membranes uring hemofiltration and heamodiafiltration. Nephrol Dial Transpl 1998;13:1535-1537.
45. Rivers L, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;145:1368-1377.
46. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: Impact on filter life and azotemic control. Nephron Clin Pract. 2003;94:c83-c84.
47. Pacitti A, Cantaluppi V, Fenoglio R, et al: Continuous hemofiltration with polyethersulfone membranes evaluated by tele-monitoring. Contrib Nephrol. Basel, Karger, 2003, vol 138, pp 126-143.
48. Bellomo R, Balwin I, Ronco C, Golper T: Atlas of Hemofiltration. London, Saunders, 2002.
49. Uchino S, Cole L, Morimatsu H, et al: Solute mass balance during isovolaemic high volume haemofiltration. Intens Care Med 2003;29:1541-1546. Epub 2003 Jul 10.
50. Morgera S, Haase M, Rocktaschel J, et al: High permeability hemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003; 18:2570-2576.
51. Tetta C, D'Intini V, Bellomo R, et al: Extracorporeal treatments in sepsis: Are there new perspectives? Clin Nephrol 2003;60:299-304.
52. Stuber F, Petersen M, Bokelmann F, Shade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384.
53. Stuber F: Another definite candidate gene for genetic predisposition of sepsis: Interleukin-10. Crit Care Med 2003;31:314-315.